Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

PBYINYSE / NASDAQHealthcareSmall cap

$7.05-$0.07 (-1.0%)

Last close · Data as of Nov 20, 2026

Market cap
$356.8M
P/E
11.5x
EV / EBITDA
6.7x
Revenue
$228.4M
Net margin
13.6%
ROCE
27.6%

+45.7% over the last year

Puma Biotechnology, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-34.5%
3M
-22.6%
6M
+0.9%
1Y
+45.7%
5Y
+106.1%

52-week range

Day change -$0.07 (-1.0%) from $7.12 to $7.05 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PBYI, bought on each weekday since 2021.

News & filings

What Puma Biotechnology filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on capital employed of 27.6%.

Concerns (1)

  • Revenue grew 0.0% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Read moreShow less

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Sector
Healthcare
Shares outstanding
50.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$356.8M
P/E
11.5x
P/B
2.7x
EV / EBITDA
6.7x
EV / Sales
1.6x
P/S
1.6x
52-week high
$11.26
52-week low
$4.84

Profitability

Operating margin
16.3%
Net margin
13.6%
EBITDA margin
23.4%
ROE
23.9%
ROCE
27.6%
ROIC
28.5%
ROA
14.4%
Asset turnover
1.06

Growth

Revenue
$228.4M
Revenue growth, 1Y
-0.9%
Revenue CAGR, 3Y
0.0%
Net profit growth, 1Y
2.8%
Free cash flow
$41.7M

Solvency

Current ratio
2.00
Debt / Equity
0.22
Debt / Assets
0.13
CFO / Net profit
1.34
Cash / Market cap
8.3%

Where the revenue went

Of every $100 of FY2025 revenue, $14 was left as net income.

Puma Biotechnology, Inc. income statement flow, FY2025
Puma Biotechnology, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$58.2M
RevenueGross profit$170.2M
Gross profitOperating expenses$132.9M
Gross profitOperating income$37.3M
Operating incomePretax income$35.8M
Operating incomeInterest and other expense$1.5M
Pretax incomeTax and other$4.7M
Pretax incomeNet income$31.1M

Revenue and net profit

Revenue fell 0.9% in FY2025; net profit is the dashed line.

Puma Biotechnology, Inc. revenue and net profit by fiscal year
Puma Biotechnology, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$228.0M$2.0k
FY2023$235.6M$21.6M
FY2024$230.5M$30.3M
FY2025$228.4M$31.1M

Cash flows

FY2025: $41.8M from operations, $41.7M free after investment (dashed).

Puma Biotechnology, Inc. operating and free cash flow by fiscal year
Puma Biotechnology, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$15.8M-$22.8M
FY2023$27.0M$14.4M
FY2024$38.9M$38.9M
FY2025$41.8M$41.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$228.4M-0.9%1Y
EBITDA
$53.3M+11.0%1Y
Net profit
$31.1M+2.8%1Y
Cash from operations
$41.8M+7.4%1Y
Free cash flow
$41.7M+7.4%1Y
Revenue CAGR, 3Y
0.0%
Net profit CAGR, 3Y
2396.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$228.4M$53.3M$31.1M$41.7M23.9%-0.9%+2.8%

Monthly returns

Month-by-month returns of PBYI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$216.3M
Liabilities$86.0M
Equity$130.3M
Paid-in capital$1.4B
Retained earnings-$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PBYI highlighted.

P/E against peers

PBYI trades at 11.5x earnings against a peer median of -2.2x.

  1. Puma Biotechnology, Inc. (this company)11.5x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Perspective Therapeutics, Inc., Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Puma Biotechnology, Inc.PBYIthis company$356.8M11.5x2.7x23.9%6.7x
Delcath Systems, Inc.DCTH$372.5M138.0x3.3x2.4%327.0x
Perspective Therapeutics, Inc.CATX$370.7M-3.6x1.8x-49.8%-3.4x
REGENXBIO Inc.RGNX$355.7M-1.8x3.5x-188.7%-3.0x
Atea Pharmaceuticals, Inc.AVIR$353.7M-2.2x1.3x-57.5%-1.4x
Greenwich LifeSciences, Inc.GLSI$347.1M-22.0x137.0x-623.1%—
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Peer median—-2.2x3.9x-157.6%-2.2x

Year-to-date ROI

PBYI since 1 January, against earlier years.

Historical volatility

PBYI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Puma Biotechnology, Inc. operating margin by fiscal year
Puma Biotechnology, Inc. operating margin by fiscal year
DateOperating margin
FY202213.5%
FY202313.9%
FY202413.4%
FY202516.3%
LineFY2025
Cost of revenueCost Of Revenue$58.2M
Gross profitGross Profit$170.2M
Operating expensesOperating Expense$132.9M
Research and developmentResearch And Development$62.1M
Provision for doubtful accountsProvision For Doubtful Accounts-$360.0k
Total expensesTotal Expenses$191.1M
Pretax incomePretax Income$35.8M

Learn while you research

Academy chapters picked for Puma Biotechnology, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 11.5 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →